Clinical Scorecard: Longitudinal Study of Local Immune Regulatory Factors in a Patient with DLBCL Vitreoretinal Lymphoma Undergoing Local Chemotherapy

At a Glance

Key Highlights

• First longitudinal analysis of vitreous immune mediators during IVT therapy.
• Key cytokines IL-10, IL-6, IL-16, IL-1RA, and sIL-2R decreased during treatment.
• Persistent chemokines CXCL12 and CXCL13 may indicate optimal treatment duration.
• High levels of hepatocyte growth factor (HGF) suggest aggressive disease.
• Dynamic changes in immune mediators correlated with clinical tumor regression.

Guideline-Based Recommendations

Diagnosis

• Diagnosis confirmed through cytopathology and elevated IL-10/IL-6 ratio.

Management

• IVT therapy with methotrexate and dexamethasone for localized ocular involvement.

Monitoring & Follow-up

• Longitudinal monitoring of vitreous immune mediators to assess treatment response.

Risks

• Chemotherapy failure rates of 15%-25% and relapse rates of 25%-50% in similar conditions.

Patient & Prescribing Data

Older adults with unilateral VRL.

IVT methotrexate (460 μg/injection) and dexamethasone (0.4 mg/injection) administered over 12 weeks.

Clinical Best Practices

• Serial vitreous sampling can provide insights into the immune microenvironment.
• Monitoring cytokine levels may guide treatment adjustments.

Related Resources & Content

• World Health Organization HAEM5 Classification
• Meta-analysis on progression-free survival rates